Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984555 · ClinicalTrials.gov registry record
Residence Time of Biomarkers of Semen Exposure
A clinical trial, sponsored by CONRAD.
- Completed
- Registry status
- 64
- Enrollment target
NCT00984555: Completed study, sponsored by CONRAD.
NCT00984555 is a clinical trial that has completed, run by CONRAD. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00984555 has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the vaginal residence time of certain semen biomarkers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-07 |
What the finished NCT00984555 record still lists
NCT00984555 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00984555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00984555 about?
NCT00984555 is a clinical study titled "Residence Time of Biomarkers of Semen Exposure". The purpose of this study is to examine the vaginal residence time of certain semen biomarkers.
What is the current status of trial NCT00984555?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2008-12. Estimated completion is 2010-07.
Who is sponsoring clinical trial NCT00984555?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia